Entero Healthcare Subsidiary Faces Three-Day Drug License Suspension
Entero Healthcare Solutions disclosed that its wholly owned subsidiary Atreja Healthcare Solutions received a three-day drug license suspension from January 30 to February 1, 2026, for violations of the Drugs and Cosmetics Act. The regulatory action by Karnal Zone authorities resulted in a potential revenue loss of ₹1.88 million, though the parent company stated no material impact on its overall operations.
*this image is generated using AI for illustrative purposes only.
Entero Healthcare Solutions has informed stock exchanges about a temporary suspension of its subsidiary's drug manufacturing license, marking a regulatory setback for the pharmaceutical company. The disclosure was made on January 27, 2026, in compliance with SEBI listing regulations.
Regulatory Action Details
The Senior Drugs Control Officer cum Licensing Authority, Karnal Zone, has temporarily suspended the drug license of Atreja Healthcare Solutions Private Limited, a wholly owned subsidiary of Entero Healthcare Solutions. The suspension is effective for three days, from January 30, 2026, to February 1, 2026.
| Parameter: | Details |
|---|---|
| Subsidiary Affected: | Atreja Healthcare Solutions Private Limited |
| Suspension Period: | 3 days (Jan 30 - Feb 1, 2026) |
| Authority: | Senior Drugs Control Officer, Karnal Zone |
| Order Receipt Date: | January 27, 2026 |
Violation Specifics
The temporary suspension was imposed as an administrative action for contraventions of provisions under the Drugs and Cosmetics Act, 1940, read with rule 64 and 65 (5) of the Drugs and Cosmetics Rules, 1945. The regulatory action was taken while Atreja was conducting its business operations.
Financial Impact Assessment
The company has provided a detailed assessment of the suspension's impact on its operations and financial performance:
| Impact Category: | Assessment |
|---|---|
| Material Impact on Parent Company: | No material impact on financial, operations or other activities |
| Potential Revenue Loss: | ₹1.88 million |
| Duration: | Three-day suspension period |
Regulatory Compliance
Entero Healthcare Solutions filed this disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.
The disclosure was signed by Sanu Kapoor, Vice President-General Counsel, Company Secretary & Compliance Officer, ensuring proper corporate governance protocols were followed in communicating this development to stakeholders and regulatory authorities.
Historical Stock Returns for Entero Healthcare Solutions
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -5.05% | -10.21% | -13.10% | +20.43% | +37.17% | +30.92% |
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
